Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02726399
Title Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

gastroesophageal junction adenocarcinoma

Therapies

Capecitabine + Cisplatin

Ramucirumab + Trastuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.